TLR9 and neoplasm: Despite good safety profiles, conventional TLR9 agonists, such as SD-101 and tilsotolimod, have resulted in varied anti-tumor responses as monotherapies or when combined with other anticancer agents following systemic administration (16–18), suggesting a need for more potent TLR9 agonists and better combination approaches.